![Matthew Ros](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 216 500 $ in data 31/05/2026
Matthew E.
Ros is currently an Independent Director at Cogent Biosciences, Inc. since 2019.
Former roles include Chief Executive Officer & Director at Fore Biotherapeutics, Inc. from 2022 to 2023; Senior Director at Bristol Myers Squibb Co. from 1990 to 2007; Senior Vice President-Commercial Operations at ARIAD Pharmaceuticals, Inc. from 2009 to 2010; Vice President & Head-Franchise at Genzyme Corp.
from 2012 to 2014; Associate Vice President at Sanofi from 2010 to 2012; COO, VP & Global Head-Oncology Business Unit at Sanofi from 2014 to 2016; Chief Financial Officer at Epizyme, Inc. in 2021; Trustee at Cancer Care, Inc.; and Chief Operating Officer at Verastem, Inc. in 2025.
Education includes an undergraduate degree from The State University of New York, conferred in 1988.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
VERASTEM, INC. 0,08% | 01/04/2025 | 50.000 ( 0,08% ) | 216 500 $ | 31/05/2026 |
| 13/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 26/07/2019 |
| Società | Posizione | Fine |
|---|---|---|
| VERASTEM, INC. | Direttore operativo | 15/12/2025 |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Amministratore Delegato | 01/08/2023 |
| EPIZYME, INC. | Direttore Finanziario/CFO | 01/10/2021 |
| SANOFI | Direttore operativo | 01/05/2016 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/12/2014 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Cogent Biosciences, Inc.
 Cogent Biosciences, Inc. BiotechnologyHealth Technology Discovers and develops new cellular immunotherapies for cancer | Health Technology |
Cancer Care, Inc.
 Cancer Care, Inc. Hospital/Nursing ManagementHealth Services Provides cancer treatment services | Health Services |
The State University of New York
 The State University of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
